BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

...alpha 13 (GNA13); integrin β3 (GPIIIa; CD61); purinergic receptor P2Y...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...Epidermal growth factor receptor 2 NTRK (Trk) - Neurotrophic tyrosine kinase receptor P2RY12 (P2Y12) - Purinergic receptor P2Y...
...RG6268, rxdx-101) Johnson & Johnson Novartis AG AbbVie Inc. Neurocrine Biosciences Inc. Shionogi & Co. Ltd. AstraZeneca plc Eli Lilly and Co. Genentech Inc. Roche Purinergic receptor P2Y...
BioCentury | Mar 1, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

...stroke in patients with acute coronary syndrome (ACS) or a history of MI. The reversible purinergic receptor P2Y...
...as Brilique. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brilinta ticagrelor Business: Cardiovascular Molecular target: Purinergic receptor P2Y...
...Status: Phase III data Milestone: Additional Phase III data (2019) Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca plc Purinergic receptor P2Y...
BioCentury | Feb 25, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

...stroke in patients with acute coronary syndrome (ACS) or a history of MI. The reversible purinergic receptor P2Y...
...P2RY12; P2Y12) inhibitor is marketed in the EU as Brilique. Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca plc Purinergic receptor P2Y...
BioCentury | Feb 1, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

...60-tablet package at a concentration of 60 or 90 mg per tablet. Brilinta, a reversible purinergic receptor P2Y...
...of Pittsburgh Medical Center, Pittsburgh, Pa. Business: Cardiovascular Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca plc University of Pittsburgh Purinergic receptor P2Y...
BioCentury | Jan 28, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

...60-tablet package at a concentration of 60 or 90 mg per tablet. Brilinta, a reversible purinergic receptor P2Y...
...how their drugs work in the real-world setting. Chris Lieu Brilinta, Brilique, ticagrelor (AZD6140, Possia) AstraZeneca plc University of Pittsburgh Purinergic receptor P2Y...
BioCentury | Dec 21, 2018
Clinical News

Idorsia's P2RY12 antagonist inhibits platelet aggregation within 15 minutes

...The company plans to meet with regulatory authorities to discuss Phase III testing of the purinergic receptor P2Y...
...Squibb Co. (NYSE:BMY). Idorsia Ltd. (SIX:IDIA), Allschwil, Switzerland Product: Selatogrel (ACT-246475) Business: Cardiovascular Molecular target: Purinergic receptor P2Y...
...MI) Endpoint: Inhibition of platelet aggregation Status: Phase II data Milestone: NA Jennie Walters ACT-246475 Plavix, clopidogrel (Iscover) Idorsia Ltd. Purinergic receptor P2Y...
BioCentury | Nov 9, 2018
Company News

AZ looks to new medicines to drive growth

...growth factor receptor (EGFR) (ErbB1) (HER1) Poly(ADP-ribose) polymerase (PARP) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Purinergic receptor P2Y...
BioCentury | Nov 8, 2018
Company News

AZ looks to new medicines to drive growth

...growth factor receptor (EGFR) (ErbB1) (HER1) Poly(ADP-ribose) polymerase (PARP) Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Purinergic receptor P2Y...
BioCentury | Oct 5, 2018
Clinical News

PhaseBio's PB2452 reverses antiplatelet activity of Brilinta in Phase I

...stroke in patients with acute coronary syndrome (ACS) or a history of MI. The reversible purinergic receptor P2Y...
Items per page:
1 - 10 of 111